Section Arrow
BBIO.NASDAQ
- BridgeBio Pharma
Quotes are at least 15-min delayed:2025/07/17 07:44 EDT
Pre Market
Last
 47.1
0 (0.00%)
Bid
46.5
Ask
49
High 47.11 
Low 45.45 
Volume 16 
Regular Hours
Last
 47.1
+0.135 (+0.29%)
Day High 
47.66 
Prev. Close
46.965 
1-M High
48.6809 
Volume 
2.59M 
Bid
46.5
Ask
49
Day Low
46.7002 
Open
47.29 
1-M Low
39.63 
Market Cap 
8.92B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 44.97 
20-SMA 43.84 
50-SMA 39.01 
52-W High 48.6809 
52-W Low 21.72 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.56/-1.98
Enterprise Value
10.64B
Balance Sheet
Book Value Per Share
-8.68
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
9.30M
Operating Revenue Per Share
0.05
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
APMAptorum Group Limited1.94+0.9702+100.04%2.77PE
Pre Market 1.77 -0.17 -8.76%
TNFATNF Pharmaceuticals Inc.0.109+0.0028+2.64%-- 
Pre Market 0.102 -0.007 -6.42%
NCNANuCana plc0.0502--0.000%-- 
Pre Market 0.0485 -0.0017 -3.39%
BRNSBarinthus Biotherapeutics plc1.42+0.4+39.22%-- 
Pre Market 1.36 -0.06 -4.23%
WINTWindtree Therapeutics Inc.0.9+0.0714+8.62%0.84PE
Pre Market 1.29 +0.39 +43.33%
Quotes are at least 15-min delayed:2025/07/17 07:44 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.